Drachneris, J.; Rasmusson, A.; Morkunas, M.; Fabijonavicius, M.; Cekauskas, A.; Jankevicius, F.; Laurinavicius, A.
CD8+ Cell Density Gradient across the Tumor Epithelium–Stromal Interface of Non-Muscle Invasive Papillary Urothelial Carcinoma Predicts Recurrence-Free Survival after BCG Immunotherapy. Cancers 2023, 15, 1205.
https://doi.org/10.3390/cancers15041205
AMA Style
Drachneris J, Rasmusson A, Morkunas M, Fabijonavicius M, Cekauskas A, Jankevicius F, Laurinavicius A.
CD8+ Cell Density Gradient across the Tumor Epithelium–Stromal Interface of Non-Muscle Invasive Papillary Urothelial Carcinoma Predicts Recurrence-Free Survival after BCG Immunotherapy. Cancers. 2023; 15(4):1205.
https://doi.org/10.3390/cancers15041205
Chicago/Turabian Style
Drachneris, Julius, Allan Rasmusson, Mindaugas Morkunas, Mantas Fabijonavicius, Albertas Cekauskas, Feliksas Jankevicius, and Arvydas Laurinavicius.
2023. "CD8+ Cell Density Gradient across the Tumor Epithelium–Stromal Interface of Non-Muscle Invasive Papillary Urothelial Carcinoma Predicts Recurrence-Free Survival after BCG Immunotherapy" Cancers 15, no. 4: 1205.
https://doi.org/10.3390/cancers15041205
APA Style
Drachneris, J., Rasmusson, A., Morkunas, M., Fabijonavicius, M., Cekauskas, A., Jankevicius, F., & Laurinavicius, A.
(2023). CD8+ Cell Density Gradient across the Tumor Epithelium–Stromal Interface of Non-Muscle Invasive Papillary Urothelial Carcinoma Predicts Recurrence-Free Survival after BCG Immunotherapy. Cancers, 15(4), 1205.
https://doi.org/10.3390/cancers15041205